ArticleFrontiers in endocrinology2026
Clinical factors associated with recurrent pregnancy loss status in women with polyendocrine metabolic ovarian syndrome.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Women with polyendocrine metabolic ovarian syndrome (PMOS) may have an increased susceptibility to recurrent pregnancy loss (RPL), but the clinical factors associated with RPL status remain incompletely characterized. This study aimed to identify factors associated with RPL status and to develop an internally validated discriminative model in women with PMOS. Methods: This retrospective, single-center study included 235 women with PMOS and at least one documented pregnancy between January 2022 and December 2025. Participants were classified into the RPL group (n = 70) or non-RPL group (n = 165). Univariable and multivariable logistic regression analyses were performed. Model discrimination, calibration, and internal validity were evaluated using receiver operating characteristic analysis and bootstrap resampling. Results: Older age (adjusted odds ratio [OR] = 1.06, 95% confidence interval [CI]: 1.01-1.12), higher body mass index (OR = 1.10, 95% CI: 1.02-1.19), infertility history (OR = 2.01, 95% CI: 1.11-3.64), higher luteinizing hormone/follicle-stimulating hormone ratio (OR = 1.77, 95% CI: 1.18-2.67), higher homeostasis model assessment of insulin resistance (OR = 1.41, 95% CI: 1.15-1.73), and higher D-dimer concentration (OR = 6.06, 95% CI: 1.92-19.15) were independently associated with higher odds of RPL status. Previous live birth was inversely associated with RPL status (OR = 0.35, 95% CI: 0.18-0.68). The model achieved an apparent area under the curve of 0.846 (95% CI: 0.791-0.901) and a bootstrap-corrected value of 0.831. Conclusions: Reproductive, endocrine, metabolic, and coagulation-related factors were associated with RPL status in women with PMOS. The resulting model showed good internal discrimination but requires external prospective validation before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.